Polyethylene glycol-interferon: Current status in hepatitis C virus therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Wedemeyer, Heiner ^a   Wiegand, Johannes ^a   Cornberg, Markus ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic hepatitis C; Hepatitis C virus; PEG interferon ; Therapy

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON DERIVATIVE; POLYETHYLENE GLYCOL ALPHA 2A INTERFERON; POLYETHYLENE GLYCOL ALPHA 2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; PRIORITY JOURNAL;

EID: 0036454791     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s3.26.x     Document Type: Conference Paper

References (35)

1. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-7.
2. Nishiguchi S, Shiomi S, Nakatani S et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196-7.
3. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
4. Carithers Jr RL, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alpha-2b trials. Hepatology 1997; 26 (Suppl. 1): 83S-88S.
5. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
6. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 1485-92.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
8. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 1999; 340: 1228-33.
9. Barrett S, Goh J, Coughlan Bet al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: Spontaneous viral clearance and chronic HCV infection. Gut 2001; 49: 423-30.
10. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000; 32: 91-6.
11. Tong MJ, El Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 1995; 332: 1463-6.
12. Di Bisceglie AM, Conjeevaram HS, Fried MW et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1995; 123: 897-903.
13. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 1998; 79: 2381-91.
14. EASL. International consensus conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J. Hepatol. 1999; 31 (Suppl. 1): 3-8.
15. Cummings KJ, Lee SM, West ES et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001; 285: 193-9.
16. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy. A meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-40.
17. Koff R. Nonresponse to interferon in chronic hepatitis C: Re-treatment redux. JAMA 2001; 285: 212-14.
18. Wedemeyer H, Jackel E, Wedemeyer J et al. Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated? An analysis of personal experiences and review of the literature. Z. Gastroenterol. 1998; 36: 819-27.
19. Zeuzem S. Treatment of chronic hepatitis C virus infection in patients with cirrhosis. J. Viral Hepatol. 2000; 7: 327-34.
20. Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The multivirc group. Gastroenterology 1999; 116: 378-86.
21. Shiffman ML, Hofmann CM, Contos MJ et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-72.
22. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997; 26: 226-31.
23. Bailon P, Palleroni A, Schaffer CA et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 2001; 12: 195-202.
24. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alpha-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin. Pharmacol. Ther. 1996; 59: 636-46.
25. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 2000; 68: 556-67.
26. Glue P, Rouzier-Panis R, Raffanel C et al. A dose-ranging study of pegylated interferon alpha-2b and ribavirin in chronic hepatitis C. Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 647-53.
27. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000; 39: 10634-40.
28. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7.
29. Modi MW, Nutley NJ, Fried M et al. The pharmacokinetic behavior of pegylated (40KDA) interferon alpha-2a (PEGASYS™) in chronic hepatitis C patients after multiple dosing. Hepatology 2000; 32 (Suppl. 2).
30. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000; 343: 1666-72.
31. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
32. Fried MW, Shiffman M, Reddy R et al. Pegylated (40kDa) interferon alpha-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively controlled, multicenter study. Gastroenterology 2001; 120: A55.
33. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000; 343: 1673-80.
34. Okuda K. Hepatocellular carcinoma. J. Hepatol. 2000; 32 (Suppl.): 225-37.
35. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alpha-2b. N. Engl. J. Med. 2001; 345: 1452-7.